microdialysates at a signal-to-noise ratio of 3 were 0.4 and 0.6 ng/ml, respectively. The proposed method was successfully applied to preliminarily study of potential pharmacokinetic interaction of Mor with diclofenac.
Introduction
Morphine (Mor) is most frequently used as an analgesic drug for both post-operative and cancer pain. The World Health Organization proposed a three-stage approach for the treatment of chronic pain, where opioids including Mor are used to be combined with non-steroidal anti-inflammatory drugs (NSAIDs). Several studies have demonstrated the benefits of the combination use of Mor with NSAIDs in comparison to Mor alone [1] [2] [3] .
These reported the additive effect on pain relief caused by the different pharmacodynamics of Mor and NSAIDs. On the other hand, although pharmacokinetic interactions between Mor and NSAIDs cannot be neglected, only limited knowledge is available [4] [5] [6] . This might be caused by a lack of simple and sensitive method for Mor determination.
Microdialysis is powerful technique to collect free drug in any tissue including the brain. Collection of drug molecule across the semipermeable microdialysis membrane makes it possible to estimate the free drug concentration in tissue. Furthermore, the clean-up procedure of the sample could be often omitted. However, since the sample size of microdialysis is generally in the microlitter range with low sample concentrations, a sensitive analytical method is required. Bengtsson et al., achieved sensitive determination of Mor and its glucuronides by using a direct injection HPLC-MS/MS [20] .
For the determination of Mor, high performance liquid chromatography (HPLC) methods with UV or DAD detection [7, 8] , electrochemical detection (ECD) [9, 10] , mass spectrometry (MS) detection [11, 12] and fluorescence detection (FL) [13] [14] [15] [16] are widely used. Quite recently, HPLC methods combined with tandem MS/MS for very low-level quantification of Mor in biological samples have been described with sub-nanogram per milliliter of quantitation limit [17] [18] [19] [20] . In the HPLC-FL detection methods, either native FL of Mor [13] [14] [15] or FL of labeled Mor [16] is used. The native FL detection method with 10-50 ng/ml of detection limits is not enough sensitive to detect very small amount of Mor. On the other hand, FL labeling is powerful technique to determine analyte sensitively and many FL labeling reagents have been utilized [21] .
However, few studies were performed for determination of labeled Mor by HPLC-FL detection because few labeling reagents for Mor were available.
4-(4,5-Diphenyl-1H-imidazol-2-yl)benzoyl chloride (DIB-Cl) could selectively label the compounds having hydroxyl group under mild conditions and produce intense fluorescence compounds. In our previous report, sensitive determination of pentazocine, a short-acting narcotic-antagonist analgesic drug, was achieved [22] .
In this study, an HPLC-fluorescence detection method using DIB-Cl as a labeling reagent was developed for determination of Mor in rat brain and blood microdialysates.
Moreover, the proposed method was applied for the study of pharmacokinetic interaction of Mor with diclofenac (Dic) after a single administration of Mor with/without Dic. 
Method validation
Calibration curves of Mor were prepared by adding Mor standard to blood or brain microdialysate to give final concentrations ranged of 5-500 ng/ml. Detection limit of Mor was defined as the concentration at a signal-to-noise (S/N) ratio of 3.
Within-and between-day assay precisions for the proposed method were assessed by using blood and brain microdialysate spiked with 25 and 250 ng/ml of Mor (n=10).
Precision was represented as a relative standard deviation (RSD, n=10). Mor for brain and blood dialysate at S/N ratio of 3 were 0.4 ng/ml (2.7 fmol on column) and 0.6 ng/ml (3.8 fmol on column), respectively. The proposed method could improve the sensitivity of Mor by more than 20 times compared to HPLC-DAD method [7, 8] and native FL method [13] [14] [15] . Furthermore, it was comparable to those of HPLC-ECD [10] and -MS/MS method [20] published recently for determination of Mor in microdialysate.
Within-and between-day precisions of the proposed method were evaluated by analyzing microdialysate spiked with known concentrations of Mor (25 and 250 ng/ml).
The within-day RSDs for brain and blood microdialysate were 7.9 (25 ng/ml) and 3.9 % (250 ng/ml), and 8.0 (25 ng/ml) and 4.3 % (250 ng/ml), respectively. Between-day precision (RSDs) of 8.4 (25 ng/ml) and 6.3 % (250 ng/ml) for brain microdialysate were obtained, while those for blood microdialysate were 8.5 (25 ng/ml) and 6.5 % (250 ng/ml).
The robustness of the proposed method was examined by changing chromatographic parameters such as column temperature (±1℃), flow rate of mobile phase (±0.05 ml/min) and pH of acetate buffer (± 0.1 unit). Each of parameters varied in the range of ±2.5%, ±4.2% and ±1.8% compared to their optimal conditions (40℃, 1.2 ml/min and pH 5.4). The percent recoveries of retention time were in the range of 97-102%. The percent recoveries of peak height were in the range of 99-104%. Since the obtained values were within the acceptable limits (95-105%) in all cases, the robustness of this HPLC method could be elucidated (Table 1 ).
Recovery of microdialysis probe
The probes used for blood and brain microdialysis were TP-20-04 (4x0.2 mm, i.d.)
and A-I-8-04 (4x0.2 mm, i.d.) cellulose membranes, respectively. In vivo recoveries of these probes for DP were calculated by using standard solutions of Mor in CSF at 50 and 500 ng/ml. Recovery and loss were calculated by following equations according to our previous report [24] . The recovery and loss factors for calculating recovery in vivo of microdialysis probe were shown in Table 2 . Subsequently, the ratios for brain and blood microdialysates were 18±6 (n=4) and 11±4 % (n=5), respectively. Table 2 
Pharmacokinetic interaction between Mor and Dic
The applicability of the proposed method was confirmed by preliminarily evaluating of potential pharmacokinetic interaction of Mor and Dic after a single administration of Mor (10 mg/kg) with/without Dic (5 mg/kg) which is an effective and frequently prescribed NSAID as described in our previous report [25] . Concentration-time profiles of Mor in rat brain and blood microdialysates after a single administration of Mor with/without Dic are shown in Fig. 3 and 4 , respectively. Mor in very small amount of microdialysate (15 µl) could be determined until 300 min after administration of medicaments by the proposed method. The pharmacokinetic parameters of Mor in brain and blood calculated by these data were summarized in Table 3 . Significant difference for any parameters could not be found between two groups in both brain and blood.
Mor was a low-transitive compound for a blood-brain-barrier, since AUC ratio (AUC brain /AUC blood ), which indicates transitivity of Mor to brain, was 0.38 in this study.
And also, 2.7 times longer T 1/2 of Mor in brain than that in blood indicated the difficulty of Mor efflux from brain. In the previous report, the AUC ratio of Mor in rat striatum was 0.22-0.28 [26] . And it was also reported that the T 1/2 of Mor in brain was significantly prolonged compared with that in blood. These results were discussed as follow: Mor was actively effluxed at the blood-brain barrier by P-glycoprotein and elimination from the central nervous system was rate-limited by redistribution of Mor from brain tissue. These were well agreed with our results.
The combination of Mor with Dic produced the benefit to the patient such as reduction of Mor consumption [27] and enhancing analgesic effect to severe pain after operation [2] . These additive effects between Mor and NSAIDs were caused by different pharmacodynamic mechanisms; opioids display their analgesic activity in the central nervous system via opioids receptors, and NSAIDs reduce the synthesis of inflammatory prostaglandins via inhibition of the enzyme cyclooxygenase [1] [2] [3] .
Ammon et al. reported that NSAIDs inhibit UDP-glucurosyltransferase in vitro study [4] . Furthermore, inhibition of renal clearance of Dic was expected as a pharmacokinetic mechanism of additive effect between Mor and Dic [3] . On the other hand, some reports were concluded that Dic did not interact pharmacokinetic of Mor in human [6] . In our condition no significant difference to pharmacokinetic parameters of Mor could found, however, applicability of the proposed method for preliminarily study of drug interaction of Mor could be confirmed. Table 3 In conclusions, an HPLC-FL detection method coupling with a microdialysis technique for determination of Mor in brain and blood microdialysates was developed.
It is confirmed that the proposed method is enough sensitive to monitor Mor in these biological fluids. Furthermore, pharmacokinetic interaction of Mor with Dic was preliminarily studied. No significant difference of almost pharmacokinetic parameters of Mor between rats administered Mor with/without Dic. However, these basic findings may help clinical inference when Mor is co-administered with Dic to human. Data are expressed as mean±SD (brain: n=4; blood: n=5). 
